目的:研究线粒体分裂抑制剂1(Mdivi-1)在实验性自身免疫性脑脊髓炎(EAE)小鼠髓鞘保护中的作用,探讨Mdivi-1抑制髓鞘变性的机制。方法:小鼠经髓磷脂少突胶质细胞糖蛋白第35~55位肽段(MOG35-55)免疫后,随机分为DMSO模型组和Mdivi-1干预组。于免疫后第28天处死小鼠,行Luxol fast blue染色分析髓鞘丢失情况,免疫荧光染色和TUNEL染色小鼠脊髓组织和体外细胞实验分析Mdivi-1髓鞘保护机制。结果:与DMSO模型组比较,Mdivi-1处理明显减少EAE小鼠脊髓组织白质区髓鞘丢失,减少少突胶质细胞凋亡及线粒体凋亡相关蛋白cleaved caspase-3、caspase-9、cytochrome C和Bax的表达;体外MO3.13少突胶质细胞培养实验发现,Mdivi-1可以明显阻止星形孢菌素(staurosporine)处理诱导的线粒体膜电位去极化,减轻细胞损伤,增强细胞活力。结论:Mdivi-1可能通过抑制少突胶质细胞线粒体相关凋亡信号通路发挥髓鞘保护作用。
目的:探讨PCSK9和MIF在乳腺癌中的水平及其临床意义。方法:选取从2021年1月至2022年12月在我院就诊的139例乳腺癌患者和125健康体检人员。测定血清及组织PCSK9和MIF水平,分析在乳腺癌中的相关性。结果:乳腺癌患者的血清PCSK9和MIF水平明显高于对照组(P Objective: To investigate the relationship between the level of PCSK9 and MIF and breast cancer. Methods: From January 2021 to December 2022, 139 breast cancer patients after surgery and 125 health people as control group were elected. The levels of propotein convertase subtilisin/kexin 9 (PCSK9) and macrophage migration inhibitory factors (MIF) were measured, and analyzed the relationship in breast cancer. Results: The serum levels of PCSK9 and MIF in breast cancer patients was significantly higher than the control group (P < 0.05). The tissue levels of PCSK9 and MIF in breast cancer patients was significantly higher than breast fibroma patients, but the difference was not statistically significant. PCSK9 levels correlated positively with MIF levels in breast cancer tissue. Conclusion: The levels of PCSK9 and MIF were related to breast cancer, and PCSK9 levels correlated positively with serum MIF levels. Through monitoring the levels of PCSK9 and MIF, the methods should provide a new theoretical basis for early diagnosis and screening of breast cancer and accurate treatment.
暂无评论